A PHASE I, OPEN-LABEL, NON-RANDOMIZED, DOSE-ESCALATING, SAFETY, TOLERABILITY, PHARMACOKINETIC, AND EFFICACY STUDY OF TAS-117 IN PATIENTS WITH ADVANCED SOLID TUMORS
Phase of Trial: Phase I
Latest Information Update: 06 Feb 2018
At a glance
- Drugs TAS 117 (Primary)
- Indications Endometrial cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Taiho Pharmaceutical
- 03 Aug 2017 Planned number of patients changed from 128 to 168.
- 03 Aug 2017 Planned End Date changed from 31 Dec 2017 to 31 Dec 2018.
- 01 Jun 2016 New trial record